Abstract
Original language | English |
---|---|
Journal | Alzheimer's and Dementia |
Early online date | 2021 |
DOIs | |
Publication status | E-pub ahead of print - 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Characteristics of subjective cognitive decline associated with amyloid positivity. / PREVENT-AD Research Group; Alzheimer's Disease Neuroimaging Initiative; FACEHBI study group.
In: Alzheimer's and Dementia, 2021.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Characteristics of subjective cognitive decline associated with amyloid positivity
AU - Janssen, Olin
AU - Jansen, Willemijn J.
AU - Vos, Stephanie J. B.
AU - Boada, Merce
AU - Parnetti, Lucilla
AU - Gabryelewicz, Tomasz
AU - Fladby, Tormod
AU - Molinuevo, José Luis
AU - Villeneuve, Sylvia
AU - Hort, Jakub
AU - Epelbaum, Stéphane
AU - Lleó, Alberto
AU - Engelborghs, Sebastiaan
AU - van der Flier, Wiesje M.
AU - PREVENT-AD Research Group
AU - Landau, Susan
AU - Alzheimer's Disease Neuroimaging Initiative
AU - FACEHBI study group
AU - Popp, Julius
AU - Wallin, Anders
AU - Scheltens, Philip
AU - Rikkert, Marcel Olde
AU - Snyder, Peter J.
AU - Rowe, Chris
AU - Chételat, Gaël
AU - Ruíz, Agustin
AU - Marquié, Marta
AU - Chipi, Elena
AU - Wolfsgruber, Steffen
AU - Heneka, Michael
AU - Boecker, Henning
AU - Peters, Oliver
AU - Jarholm, Jonas
AU - Rami, Lorena
AU - Tort-Merino, Adrià
AU - Binette, Alexa Pichet
AU - Poirier, Judes
AU - Rosa-Neto, Pedro
AU - Cerman, Jiri
AU - Dubois, Bruno
AU - Teichmann, Marc
AU - Alcolea, Daniel
AU - Fortea, Juan
AU - Sánchez-Saudinós, M. Belén
AU - Ebenau, Jarith
AU - Pocnet, Cornelia
AU - Eckerström, Marie
AU - Thompson, Louisa
AU - Villemagne, Victor
AU - Buckley, Rachel
AU - Burnham, Samantha
AU - Delarue, Marion
AU - Freund-Levi, Yvonne
AU - Wallin, Åsa K.
AU - Ramakers, Inez
AU - Tsolaki, Magda
AU - Soininen, Hilkka
AU - Hampel, Harald
AU - Spiru, Luiza
AU - Tijms, Betty
AU - Ossenkoppele, Rik
AU - Verhey, Frans R. J.
AU - Jessen, Frank
AU - Visser, Pieter Jelle
N1 - Funding Information: Pieter Jelle Visser reports receiving research support from ZonMW (Redefining AD), from ZonMW (Netherlands Consortium of Dementia Cohorts (NCDC), from Innovative Medicine Initiatives (IMI) (Amypad), from IMI (RADAR‐AD), and from Biogen (Amyloid biomarker study group). All payment were made to institution. He also reports receiving payment for Workshop grant writing organized by Synapsis; patent PCT/NL2020/050216, and is Senior editor Alzheimer Research and Therapy and Biomed Central (BMC) Geriatrics and a Member of the Executive board of European Alzheimer's Disease Cohorts (EADC). Funding Information: Lucilla Parnetti reports receiving funds for clinical trials from INDENA S.P.A., Biogen, EISAI Co., Ltd.; payments were made to University of Perugia, Department of Medicine and Surgery. ‐ From 2019: MIRIADE funded under Marie Skłodowska‐Curie actions by the European Union's Horizon 2020 research and innovation programme. Payments were made to University of Perugia. From 2019: bPRIDE project funded by the European Joint Programming on Neurodegenerative Diseases (JPND, European Union's Horizon 2020 research and innovation programme). Payments were made to University of Perugia; is member of the Editorial Board of the following journals (unpaid): • Neurology • Movement Disorders • Biomolecules • Scientific Reports • Frontiers in Aging Neuroscience • Cells • Journal of Alzheimer Disease • Biomarker Insights • Journal of Integrative Neuroscience Lucilla Parnetti is member of the following societies (unpaid): ‐ Since 2019: Member of the Fresco Network for Parkinson's disease. ‐ Since 2020: Member of the Research Council of Norway, Member of the Icelandic Centre for Research, Coordinator of a Center of Excellence of the Parkinson Foundation; and received Lumipulse kits from Fujirebio and ELISA kits from Euroimmun (2021) Funding Information: Research of Alzheimer Centre Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Centre Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The SCIENCe project is supported by research grants from Gieskes‐Strijbis fonds and stichting Dioraphte. Wiesje van der Flier holds the Pasman chair. Funding Information: Rachel Buckley reports research support from NIH‐NIA K99/R00 Pathway to Independence award Alzheimer's Association Research Fellowship and Alzheimer's Association International Conference travel fellowship (2019). Funding Information: The present study was supported by European Medical Information Framework (EMIF)‐AD. The EMIF‐AD project has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007‐2013) and EFPIA companies’ in kind contribution. Funding Information: Judes Poirier reports support provided by the Fonds de la Recherche en Santé du Québec and the JL Levesque Foundation and has served at the scientific advisory board of the CIHR and Alzheimer Foundation of France. Funding Information: The Imagerie Multimodale de la maladie d'Alzheimer a un stade Precoce (IMAP) study (G Chételat, Caen) was supported by the Programme Hospitalier de Recherche Clinique (PHRCN 2011‐A01493‐38 and PHRCN 2012 12‐006‐0347), the Agence Nationale de la Recherche (ANR LONGVIE 2007), Fondation Plan Alzheimer (Alzheimer Plan 2008–2012), Association France Alzheimer et maladies apparentées AAP 2013, the Région Basse Normandie and the Institut National de la Santé et de la Recherche Médicale (INSERM). Funding Information: The Sant Pau Memory Unit has received funding from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Instituto de Salud Carlos III; jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa”; Generalitat de Catalunya; Fundació "La Marató TV3” Fundació Bancària Obra Social La Caixa; Fundación BBVA; Fundación Española para el Fomento de la Investigación de la Esclerosis Lateral Amiotrófica (FUNDELA); Global Brain Health Institute; Fundació Catalana Síndrome de Down; and Fundació Víctor Grífols i Lucas. Funding Information: Julius Popp reports receiving support from Synapsis Foundation Alzheimer Swiss (to institution; Swiss National Research foundation (to institution); Om Pharma Switzerland (to institution), and receiving consulting fees from Om pharma Switzerland (to institution). Funding Information: Marta Marquié receives research support from the Instituto de Salud Carlos III (ISCIII) grant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER‐“Una manera de Hacer Europa). Funding Information: Merce Boada reports receiving research support from Grifols and the Instituto de Salud Carlos III (ISCIII) grant; receiving consulting fees; and participating on Data Safety Monitoring Board or Advisory Board from Biogen, Roche, Merck, Zambon, Cortexyme. Funding Information: Stephanie Vos reports receiving a personal grant from ZonMw, and research support from Alzheimer Nederland and Stichting Rinsum Ponssen. Funding Information: Gaël Chételat has received research support from the European Union's Horizon 2020 research and innovation program (grant agreement No. 667696), Inserm, Fondation d'entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, Région Normandie, Association France Alzheimer et maladies apparentées, and Fondation Vaincre Alzheimer (all to Inserm); and personal fees from Fondation d'entreprise MMA des Entrepreneurs du Futur. No stock options, patents, or royalties. Funding Information: A proportion of data used in preparation of this article were obtained from the LeARN study and prepared by Ron Handels. The LeARN study was performed within the framework of CTMM, the Center for Translational Molecular Medicine, a Dutch public‐private partnership; project LeARN (grant 02 N‐101). Funding Information: Harald Hampel is an employee of Eisai Inc. and serves as Senior Associate Editor for the journal and does not receive any fees or honoraria since May 2019. Before May 2019 he had received lecture fees from Servier, Biogen, and Roche; research grants from Pfizer, Avid, and MSD Avenir (paid to the institution); travel funding from Eisai, Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE‐Healthcare, and Oryzon Genomics; consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation; and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics, and Roche Diagnostics. He is co‐inventor in the following patents as a scientific expert and has received no royalties: In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784; Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300; In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463; In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286; In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822; In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553; CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797; In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966; Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921. This work has been performed during his previous position at Sorbonne University, Paris, France. At Sorbonne University he was supported by the AXA Research Fund, the “” and the “,” Paris, France. Alzheimer's & Dementia Fondation partenariale Sorbonne Université Fondation pour la Recherche sur Alzheimer Funding Information: The Fundació ACE Healthy Brain Initaitive (FACEHBI) study was supported by funds from Fundació ACE Institut Català de Neurociències Aplicades, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Funding Information: Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH‐12‐2‐0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. A proportion of data used in preparation of this article were obtained from the Pre‐symptomatic Evaluation of Novel or Experimental Treatments for Alzheimer's Disease (PREVENT‐AD) program (htpp://douglas.research.mcgill.ca/stop‐ad‐centre), data release 5.0 (November 30, 2017). As such, the investigators of the PREVENT‐AD program contributed to the design and implementation of PREVENT‐AD and/or provided data but did not participate in analysis or writing of this report. A complete listing of PREVENT‐AD Research Group can be find in the PREVENT‐AD database: http://preventad.loris.ca/acknowledgements/acknowledgements.php?date = [2020 = 04‐01]. Funding Information: Daniele Altomare received research support from Institute of Health Carlos III (ISCIII), Spain research grants PI18/00435 and INT19/00016 to DA Department of Health Generalitat de Catalunya PERIS research program SLT006/17/125 to DA; consulting fees for his participation in advisory boards from Fujirebio‐Europe and Roche Diagnostics; speaker honoraria from Fujirebio‐Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A.; and support for attending meetings from Nutricia. Funding Information: Jakub Hort reports research support from Czech Ministry of Health and honoraria for lectures by Schwabe and Lundbeck, as well as travel grant from Czech grant agency and participating in a Data Safety Monitoring Board or Advisory Board from Axon company and having stock options in Alzheon company. Funding Information: Wiesje M van der Flier reports receiving research funding from ZonMW, NWO, EU‐FP7, EU‐JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life‐MI, AVID, Roche BV, Fujifilm, and Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape). All funding is paid to her institution; and she is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc, and is associate editor at . Alzheimer's, Research & Therapy Funding Information: Agustin Ruíz receives research support from the Innovative Medicines Initiative 2 Joint Undertaking, which receives support from the European Union's Horizon 2020 research and innovation programme (ADAPTED Grant No. 115975). AR's research is also supported by Instituto de Salud Carlos III (ISCIII) grants PI16/01861 and PI19/01301. Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and funded by ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER‐“Una manera de Hacer Europa) and JPco‐fuND‐2 “Multinational research projects on Personalised Medicine for Neurodegerative Diseases” PREADAPT project, and reports consulting fees from Landsteiner Genmed, Grifols, Araclon biotech and lecture fees from Araclon Biotech; has EU Patent EP21382305.7; and participated on Data Safety Monitoring Board or Advisory Board of Grifols SA and Landsteiner Genmed. Funding Information: Juan Fortea reports funding from Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III, to my institution; National Institutes of Health, to institution; Fundació La Marató de TV3, to my institution; Generalitat de Catalunya, to institution; Fundació Catalana Síndrome de Down, to institution; and ‐Fundació Víctor Grífols i Lucas; and has served as a consultant for Novartis and Lundbeck, has received honoraria for lectures from Roche, NovoNordisk, Esteve, and Biogen; has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued; and has served at advisory boards for AC Immune, Zambon, and Lundbeck, as well as institution received support from AC Immune to acquire Quanterix NfL Kits. Funding Information: Samantha Burnham reports receiving research support from grants NHMRC GNT1161706, NHMRC GNT1156891, NHMRC GNT1191535, NHMRC GNT2001320, and NHMRC MRFF117 1338. Funding Information: PI17/01474 Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER‐Una manera de hacer Europa), and reports consulting fees from Grifols, Araclon, Biogen, Roche. Lilly, Schwabe, Cortexyme, Merck and Nutricia. Publisher Copyright: © 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2021
Y1 - 2021
N2 - Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
AB - Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
KW - Alzheimer's disease
KW - amyloid
KW - cerebrospinal fluid
KW - positron emission tomography
KW - subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85120831306&partnerID=8YFLogxK
U2 - 10.1002/alz.12512
DO - 10.1002/alz.12512
M3 - Article
C2 - 34877782
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
SN - 1552-5260
ER -